EWM
DFTX

Endowment Wealth Management’s Definium Therapeutics DFTX Stock Holding History

Endowment Wealth Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
+4,793
New +$118K 0.09% 157
2022
Q3 		– Sell
-928
Closed -$9K – 119
2022
Q2 		$9K Buy
928
+100
+12% +$1.26K 0.01% 113
2022
Q1 		$14K Buy
+828
New +$14.4K 0.01% 123

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Endowment Wealth Management's DFTX Position: Q2 2026 in Review

Endowment Wealth Management opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 4,793 shares worth $225K. The stake represents 0.09% of the portfolio and ranks #157 among its holdings. This is a return to the name: Endowment Wealth Management previously reported a position in DFTX as recently as Q2 2022.

Endowment Wealth Management first reported a position in DFTX in Q1 2022 and has held it in 3 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Endowment Wealth Management held 4,793 shares of Definium Therapeutics worth $225K as of Q2 2026.
  • Definium Therapeutics was a new Endowment Wealth Management position in Q2 2026.
  • Definium Therapeutics made up 0.09% of Endowment Wealth Management's portfolio in Q2 2026, its #157 holding.
  • Endowment Wealth Management first reported a position in Definium Therapeutics in Q1 2022 and has held it in 3 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Endowment Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.